Revefenacin, a Once-Daily, Lung-Selective, Long-Acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-Week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Respiratory Medicine - United Kingdom
doi 10.1016/j.rmed.2019.05.010
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Long-Term Safety Study of Infliximab in Moderate-To-Severe Chronic Obstructive Pulmonary Disease

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Differences in Symptom Burden Among Patients With Moderate, Severe, or Very Severe Chronic Obstructive Pulmonary Disease

Journal of Pain and Symptom Management
NeurologyAnesthesiologyPain MedicineNursing
2016English

Daily Home-Based Spirometry During Withdrawal of Inhaled Corticosteroid in Severe to Very Severe Chronic Obstructive Pulmonary Disease

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2016English

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease

Drugs - Real World Outcomes
Pharmacology
2019English

Pd50-06 Long-Term Safety and Tolerability of Oral Testosterone (Lpcn 1021) in Hypogonadal Men: Results From the 52-Week Phase 3 Study

Journal of Urology
Urology
2016English

A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/Salmeterol in Moderate to Very Severe COPD

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2013English

Efficacy and Safety of Continuous Every 2-Week Dosing of Ixekizumab Over 52 Weeks in Patients With Moderate-To-Severe Plaque Psoriasis in a Randomized Phase 3 Trial (IXORA-P)

British Journal of Dermatology
DermatologyMedicine
2018English

Safety and Tolerability of Low-Dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease

Journal of Clinical Gastroenterology
Gastroenterology
2013English

The Lung Tissue Microbiota of Mild and Moderate Chronic Obstructive Pulmonary Disease

Microbiome
Microbiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy